Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Mixed Results With TMB as NSCLC Marker

Key clinical point: Tumor mutational burden (TMB) needs further refinement as a marker for non-small cell lung cancer (NSCLC).

Major finding: High TMB was significantly more frequent in metastases than primary tumors.

Study details: Analysis of samples from 3,424 patients with NSCLC.

Disclosures: The investigators did not report a study funding source. Dr. Stein reported no relevant disclosures. Several of the coauthors are employees of Caris Life Sciences, which performed the tumor profiling.


Stein MK et al. JCO Precision Oncology. 2019 Jul 26. doi: 10.1200/PO.18.00376.